Interferon-alpha induces bcl-2 proto-oncogene in patients with neuroendocrine gut tumor responding to its antitumor action

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4659-4665

  Imam, Hassan ^a   Gobl, Anders ^a   Eriksson, Barbro ^a   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bcl 2; IFN ; Somatostatin analog

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; OCTREOTIDE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GENES, BCL-2; HUMANS; INTERFERON ALFA-2B; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PEPTIDES, CYCLIC; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SOMATOSTATIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031409309     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61(5): 759-767, 1990.
2. Korsmeyer SJ: Bcl-2: an antidote to programmed cell death. Cancer Surv (UNITED STATES) 15: 105-118, 1992.
3. Kerr JFR, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
4. Schwartz LM and Osborne BA: Programmed cell death, apoptosis and killer genes. Immunol Today 14 (12): 582-590, 1993.
5. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11(2): 121-139, 1992.
6. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (UNITED STATES) 2: 275-280, 1990.
7. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U.S.A. 83(14): 5214-5218, 1986.
8. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348(6299): 334-336, 1990.
9. Hockenbery DM: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A 88 (16): 6961-6965, 1991.
10. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52(24): 6940-6944, 1992.
11. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86(7): 499-504, 1994.
12. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71(5): 1003-1007, 1995.
13. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C and Pleasure D: Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51(24): 6529-6538, 1991.
14. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC and Reed JC: Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146(3): 643-650, 1995.
15. Hague A, Moorghen M, Hicks D, Chapman M and Paraskeva C: BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 9(11): 3367-3370, 1994.
16. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329(10): 690-694, 1993.
17. Henriksen R, Wilander E and Oberg K: Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 72(5): 1324-1329, 1995.
18. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74(4): 609-619, 1993.
19. Creasey AA, Bartholomew JC and Merigan TC: Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77(3): 1471-1475, 1980.
20. Sokawa Y, Watanabe Y, Watanabe Y and Kawade Y: Interferon suppresses the transition of quiescent 3T3 cells to a growing state. Nature. 268(5617): 236-238, 1977.
21. Matarese GP and Rossi GB: Effect of interferon on growth and division cycle of Friend erythroleukemic murine cells in vitro. J Cell Biol 75(2 Pt 1): 344-354, 1977.
22. Oberg K: The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 3(1): 35-41, 1992.
23. Lapis K, Timar J, Neill J and Mulchahey J: Cellular and molecular aspects of apoptosis in experimental tumors of animals treated with analogs of LHRH and Somatostatin. In: Apoptosis: The Molecular Basis of Cell Death.(L.D. Tomei and F.O. Cope, eds). New York, Cold Soring Harbor Laboratory Press., 1991, pp 139-155.
24. Lamberts SW, van der Lely AJ, de Herder WW and Hofland LJ: Octreotide. N Engl J Med (UNITED STATES) 334(4): 246-254, 1996.
25. Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G, Heldin CH and Oberg K: Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer-Res 50(3): 748-753, 1990.
26. Hsu DW, Efird JT and Hedley-Whyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147(1): 114-123, 1995.
27. Novou G: PCR in situ hybridization. Protocols and Applications. In: eds). New York, Raven Press, 1994, pp
28. Umansky SR: The genetic program of cell death. Hypothesis and some applications: transformation, carcinogenesis, ageing. J Theor Biol 97(4): 591-602, 1982.
29. Adam B and Jeffrey C: Bcl-2: Physiology and role in neoplasia. In: Oncogenes and tumor suppressor genes in human malignansies. (C.C. Benz. and E.T. Lie., eds) Boston, Kluwer Academic Publishers., 1993, pp 141-166.
30. Barinaga M: Cell suicide: by ICE, not fire. Science 263(5148): 754-756, 1994.
31. Imam H, Eriksson B, Lukinius AET, Janson ET, Lindgren PG, Wilander E and Oberg K: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with Somatostatin analogs. Acta Oncologica, In press.
32. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG and Reed JC: Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145(6): 1323-1336, 1994.
33. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood (USA) 88(2): 386-401, 1996.
34. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, Bloigu R, Lehto VP and Paakko P: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 55(23): 5595-5602, 1995.
35. Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH and Bergan A: Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 30(8): 789-796, 1995.